BCR and prostate cancer: Moreover, the detection rates of <sup>18</sup>F-labeled choline, fluciclovine, and PSMA were 35, 23, and 58% for a PSA level less than 0.5 ng/ml; 41, 46, and 75% for a PSA level of 0.5-0.99 ng/ml; 62, 57, and 86% for a PSA level of 1.0-1.99 ng/ml; 80, 92, and 94% for a PSA level more than 2.0 ng/ml.<h4>Conclusion</h4>These three <sup>18</sup>F-labeled tracers are promising for detecting BCR in prostate cancer patients, with <sup>18</sup>F-choline showing superior diagnostic accuracy.